Unlike for individuals or entities providing or receiving services related to in vitro fertilization (IVF), the Alabama IVF Act does not grant immunity to manufacturers, but it limits damages for their violations to the cost of an IVF cycle.

Carta Healthcare’s co-founder discusses how a recent ruling on non-compete clauses may help alleviate the coming nursing shortage.

The NABIP expressed frustration at CMS’ statement for placing blame on brokers and agents and not acknowledging evidence that switches were made by automated programs.

Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and the company founders.

Roche’s human papillomavirus solution is reportedly one of the first of its kind to be available in the United States.

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora discusses ways that cell and gene therapy developers can follow examples from the commercialization and distribution of orphan drugs.

The latest news for pharma industry insiders.

The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.

In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes.

Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora discusses the process of coming up with innovative order-to-cash solutions to help maximize market reach.

The CEO of ActiGraph discusses how these devices are changing patient monitoring in clinical trials.

The latest news for pharma industry insiders.

Industry experts, in a roundtable discussion, explore the evolution of brand engagement in the age of AI, including the growing importance of message relevance—and, for pharma, going where the information is.

Designing an effective travel and lodging patient hub program in pharma.

Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled.

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing significant support.

Led by Decheng Capital, the successful round of funding also included participation from investors such as Cormorant Asset Management, Surveyor Capital, and the Foundation for Prader-Willi Research.

The latest news for pharma industry insiders.

These factors provide investors with enough information to identify promising investment opportunities.

A greater shift from paper records and physical assets is achievable.

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors.

Now-unclear timing on rate cuts puts onus back on fundamentals.

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients.